| Talecris Infusion Could Save or Sink Grifols EP Vantage submits:Monday’s announcement that Grifols (GIKLY.PK) will be acquiring Talecris Biotherapeutics (TLCR) shows that size does matter, at least when it comes to blood products. The rationale for the deal appears to be the increasing competition in the blood plasma world, and, as such, the companies that can drive economies of scale should stand a better chance of succeeding. Grifols will be paying $3.2bn for Talecris in a mixture of cash and shares, with the $26.16 per share price tag being made up of $19 in cash and the rest in non-voting shares. Investors, however, reacted negatively to the empire-expanding move, pushing shares in Grifols down by 7% by late afternoon trading to €8.61.Complete Story » seekingalpha.com |
Benefits of Teens Sleeping Later Starting school just 30 minutes later was linked with significant improvements in adolescents' reported sleep times, mood and health, according to a new study. online.wsj.com |
Abbott Eyes India for Shot in Arm India's market leader in medicines will soon be based near Lake Michigan. Abbott will hold the biggest share of India's pharmaceuticals market when the company closes its $3.7 billion takeover of the drugs business of Piramal Healthcare. online.wsj.com |
Top 5 Upcoming FDA Decisions With Bullish Options Sentiment Kapitall submits:The following is a list of 5 FDA decisions with bullish options sentiment.To create the list, we started with a universe of biotech stocks that have FDA decisions scheduled over the next month. We then narrowed down the list to focus on the top 5 stocks in terms of the Put/Call ratio (based on open options positions).Complete Story » seekingalpha.com |
GM IPO Frenzy Fails to Ignite Biotech Offerings The Burrill Report submits: By Michael FitzhughInvestor enthusiasm for the oversubscribed $20 billion General Motors (GM) initial public offering failed to carry over to the biotech sector where a flurry of issues raced to capture some of the excitement sparked by the carmaker’s record offering before the holiday lull. IPOs by Zogenix (ZGNX) and Anacor Pharmaceuticals (ANAC) here, as well as Zealand Pharma in Europe, all debuted to tepid market interest, each pricing well below what company managers hoped to fetch. Complete Story » seekingalpha.com |